{
  "name" : "dacemirror.sci-hub.se_journal-article_16d8f09c4c8aa3b4518ba3906884d000_boyle2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Cellular Target of a Rhodium Metalloinsertor is the DNA Base Pair Mismatch",
    "authors" : [ "Kelsey M. Boyle", "Adela Nano", "Catherine Day", "Jacqueline K. Barton" ],
    "emails" : [ ],
    "sections" : null,
    "references" : [ {
      "title" : "This article is protected by copyright",
      "author" : [ "K.C.G. Berg", "P.W. Eide", "I.A. Eilertsen", "B. Johannessen", "J. Bruun" ],
      "venue" : "All rights reserved",
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2017
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "[12,13] These cell lines represent a diverse set of tumors, spanning the four subtypes of CRC and both MMR− and MMR+ phenotypes.[14,15] The toxicities of RhPPO, which selectively targets MMR deficiencies, and the non-selective FDA-approved chemotherapeutic cisplatin, which covalently binds the abundant d(GpG) motifs present in all DNA (Figure 1), were assessed in this cell line panel using a luciferase-based luminescence assay which measures ATP from living cells.",
      "startOffset" : 128,
      "endOffset" : 135
    } ],
    "year" : 2019,
    "abstractText" : "Defects in DNA mismatch repair (MMR) are commonly found in various cancers, especially in colorectal cancers. Despite the high prevalence of MMR-deficient cancers, mismatch-targeted therapeutics are limited and diagnostic tools are indirect. Here, we examine the cytotoxic properties of a rhodium metalloinsertor, [Rh(phen)(chrysi)(PPO)]2+ (RhPPO) in 27 diverse colorectal cancer cell lines. Despite the low frequency of genomic mismatches and the non-covalent nature of the RhPPO-DNA lesion, RhPPO is on average 5 times more potent than cisplatin. Importantly, the biological target and profile for RhPPO differs from that of cisplatin. A fluorescent metalloinsertor, RhCy3, was used to demonstrate that the cellular target of RhPPO is the DNA mismatch. RhCy3 represents a direct probe for MMR-deficiency and correlates directly with the cytotoxicity of RhPPO across different cell lines. Overall, our studies clearly indicate that RhPPO and RhCy3 are promising anticancer and diagnostic probes for MMR-deficient cancers, respectively. Deficiencies in cellular mismatch repair (MMR) machinery are a hallmark of 14% of colorectal cancer cases and up to 20% of all solid tumors.[1,2] Cells with MMR-deficiencies (MMR−) cannot repair DNA mismatches or insertions/deletions (indels), leading to a relative abundance of these lesions in these cells. Mismatches could thus serve as a unique druggable target that has yet to be utilized in a clinical setting. Furthermore, these lesions could serve as a target for direct detection and diagnosis of MMR deficiencies in tumors, something that is commonly measured indirectly through tests of mutational frequency in microsatellite regions instead of number of mismatches.[2b] Such a diagnostic would further support the promise of a mismatchand indeltargeted therapeutic agent. Our group and others have addressed this need through the development of mismatch-targeted small molecules.[3] Specifically, our group has developed a unique family of metal complexes, called rhodium metalloinsertors, that can selectively target thermodynamically destabilized regions of DNA, such as base pair mismatches (Figure 1), small indels, and abasic sites, making the metal complexes an ideal candidate for targeting and detecting the DNA lesions found in MMR-deficient tumors.[4–7] Rhodium metalloinsertors have been rigorously studied in several pairs of matched cancer cell lines which differ primarily in the presence or absence of functioning MMR machinery.[8,9] In every matched pairing, metalloinsertors are significantly more cytotoxic towards the MMR− cell line compared to their MMRproficient (MMR+) counterpart (a feature referred to as selectivity). These results demonstrate that rhodium metalloinsertors can target MMR deficiencies in cells, however they do not prove the specific cellular target of metalloinsertors to be DNA mismatches. Furthermore, these cell pairings are not reflective of the diversity of clinical colorectal cancer (CRC) cases; in reality, the differences between tumors in two different patients or healthy and cancerous tissues in a single patient will be far greater than just the presence or absence of a single MMR protein.[10,11] Figure 1. The binding and structure of a metalloinsertor and cisplatin. As observed crystallographically in previous studies, a classic metalloinsertor binds selectively to a mismatch in DNA (top left, PDB 3GSK), while cisplatin binds to a d(GpG) site in DNA (top right, PDB 1AIO). The structures of RhPPO (middle left), cisplatin (middle right), and RhCy3 (bottom). To understand more fully the potential clinical applicability of rhodium metalloinsertors, we examined our most potent and selective metalloinsertor, [Rh(phen)(chrysi)(PPO)]Cl2 (RhPPO, Figure 1), across 27 CRC cell lines (Table S1).[12,13] These cell lines represent a diverse set of tumors, spanning the four subtypes of CRC and both MMR− and MMR+ phenotypes.[14,15] The toxicities of RhPPO, which selectively targets MMR deficiencies, and the non-selective FDA-approved chemotherapeutic cisplatin, which covalently binds the abundant d(GpG) motifs present in all DNA (Figure 1), were assessed in this cell line panel using a luciferase-based luminescence assay which measures ATP from living cells. Dose-response curves and corresponding IC50 values (50% inhibitory concentration) were determined for each therapeutic and are shown in Figure 2 and Table S2. The IC50 values of RhPPO in different cell lines span nearly three orders of magnitude, ranging from 63 ± 3 nM to 18 ± 3 μM. Despite the low number of genomic mismatches, RhPPO is more potent than cisplatin in nearly every cell line, with the IC50 values of RhPPO being on average 5 times lower than those of cisplatin (2.9 μM vs. 13.2 μM, respectively). This result is remarkable considering that DNA mismatches are significantly less abundant than d(GpG) sites and metalloinsertors interact only through non-covalent stacking with these mismatches. The potency of a therapeutic in cell culture has long been considered H3N Pt",
    "creator" : "pdftk 2.02 - www.pdftk.com"
  }
}